Clinical Pipeline
Shattuck’s lead partnered compound entered the clinic in April 2019, and its lead wholly-owned compound entered the clinic in August of 2020.
To date, Shattuck’s Agonist Redirected Checkpoint (ARC) platform has yielded more than 300 bi-functional fusion protein drug candidates, two of which are currently in clinical trials for the treatment of life-threatening and debilitating diseases. The two lead ARC molecules are designed to block checkpoint molecules that limit the immune system (PD-1 and CD47) while simultaneously stimulating T-cell receptors to initiate an immune response (OX40 or CD40). Shattuck’s lead partnered asset, SL-279252 (PD1-Fc-OX40L), has advanced to the clinic in less than two years and is currently enrolling patients at five sites across the United States, Canada, and Europe. Shattuck’s internal lead asset, SL-172154 (SIRPα-Fc-CD40L), began enrolling patients in its clinical trials during the second half of 2020.
| Platform | Program | Domain 1 | Domain 2 | Indications | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Anticipated Milestones / Status |
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical-Stage Pipeline | ||||||||||
| ARC | SL-172154 | SIRPα | CD40L | Ovarian Cancer |  | Initial Dose Escalation Data 2H'2021 | ||||
| ARC | SL-172154 | SIRPα | CD40L | CSCC and HNSCC(1) | | Initial Dose Escalation Data 1H'2022 | ||||
| ARC | SL-279252 | PD-1 | OX40L | Advanced Solid Tumors and Lymphoma | | Dose Escalation Data 2H'2021 | ||||
| Select Preclinical-Stage Pipeline | ||||||||||
| ARC | SL-115154 | CSF1R | CD40L | Advanced Solid Tumors | | Manufacturing | ||||
| ARC | SL-9258 | TIGIT | LIGHT | Oncology | | Manufacturing | ||||
| ARC | SL-279137 | PD-1 | 4-1BBL | Oncology | | Non-Clinical Dev. | ||||
| ARC | SL-6159 | CD86 | NKG2a | Oncology | | Lead Selection | ||||
| ARC | Multiple | Undisclosed | Undisclosed | Autoimmune | | Lead Selection | ||||
| GADLEN | Multiple | γδ TCR | Tumor Antigen | Oncology | | Lead Candidate Selection 2021 | ||||
(1) Cutaneous Squamous Cell Carcinoma (CSCC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
Takeda holds exclusive options to license SL-279252 and SL-115154
